UNSPSC 51382902: Ibuproxam

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O3LD16O96Z, chemically known as propionohydroxamic acid, 2-(p-isobutylphenyl)-, d,l- but generally known as ibuproxam, which bears US NIH Compound Identifier 68704. European Medicines Agency schedules Ibuproxam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08099MIG.

UNSPSC 51382902 Ibuproxam is a Commodity code that captures pharmaceuticals and over-the-counter health products procured by state and local health agencies, though the recent opportunities in the code show a broader pattern of pharmaceutical supply and distribution activities rather than ibuprooxam-specific purchasing. State and local governments acquire these products through health departments, county public health offices, and multistate cooperative purchasing alliances to support community health initiatives, emergency response programs, and routine clinical operations. Issuing bodies include county health departments (Seminole County, Florida), state HHS commissions (Texas Health and Human Services Commission), and regional cooperative purchasing entities (Minnesota Multistate Cooperative Purchasing Alliance, serving multiple states including Oregon). The scope of work encompasses competitive bidding for pharmaceutical inventory, direct-to-manufacturer prescription program development, and establishment of master contracts with authorized wholesaler networks for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities.

Recent activity spans the South (Florida), Southwest (Texas), and Upper Midwest (Minnesota and participating states including Oregon). Representative opportunities include Seminole County's IFB60459723LAS, an IFB for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries due July 26, 2023 (Seminole County Community Health Building, Sanford, Florida); the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, establishing contracts effective July 1, 2026 with pricing weighted 75 percent on competitiveness and requiring compliance with cGMP, the Drug Supply Chain Security Act, and relationships with authorized wholesalers AmerisourceBergen, Cardinal Health, and Morris & Dickson.